VZV-specific-GD2-CAR

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVZV-specific-GD2-CAR
Drug Alias NameiC9-GD2-CAR-VZV-CTLsVZV-specific-GD2-CAR
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionDisialoganglioside GD2 modulatorsT lymphocyte replacements
TargetsDisialoganglioside GD2
Therapy Area/IndicationsSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of MedicineNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesMethodist Hospital SystemTexas Children'S HospitalNational Cancer Institute +[4] 
Inactive CompaniesN/A
Active IndicationsSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A